ClinicalTrials.gg
CompletedNCT02640950Updated Jun 1, 2022Results posted

An Open Label Trial of TMS Therapy for Bipolar Depression

An interventional study of NeuroStar TMS in Bipolar Depression, sponsored by Sheppard Pratt Health System. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by Sheppard Pratt Health System · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 836 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Enrollment
479th of 703
31 · median 58
Started
2015
with 27 others
No phase
276 of 836
37 open now
Registered
555th of 836
by date

Among the 836 studies in Bipolar Disorder with a site in United States, this one is the 479th largest by enrollment of the 703 interventional ones that give a count, is one of 28 that started in 2015, is one of 276 with no phase, and was the 555th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 836 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 836 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

Transcranial Magnetic Stimulation (TMS) is an increasingly accepted neurostimulation- based treatment for major depressive disorder. While there is a growing anecdotal database supporting its use in bipolar depression the investigators propose to collect open label efficacy and safety data in a small population of patients with clinically verified bipolar disorder.

Read the detailed description

The investigators propose to screen patients with bipolar depression I or II, who are already on acceptable mood stabilization. They may or may not be on antidepressants at the time of screening but subjects on antidepressants would be taken off them before completing the screening phase. Those patients who have a depression of at least moderate severity without significant symptoms of activation or mania will be started on a course of open label TMS treatment of up to 35 sessions. Safety and efficacy assessments will be done weekly. Patients will complete a course of treatment when they meet remission criteria (MADRS score \< 10) or at the end of 30 treatments, whichever comes first. Patient who are still judged to be improving between treatment 25 and treatment 30 will be eligible to complete up to five addition treatments as the discretion of each site's principal investigator. Patients who meet response criteria (MADRS score decreases by at least 50%) will complete the full course of 30 to 35 TMS sessions. Patients will be withdrawn for safety concerns, particularly the onset of activation suggestive of mania or a mixed state.

Patients who meet response or remission criteria will be followed monthly for up to six months to evaluate the durability of response. They will be on standard mood stabilizing medications and psychotherapy per their clinician's discretion.

03

Conditions studied

  • Bipolar Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be at least 18 years old.
  2. Must meet criteria for bipolar (either I or II) depression by clinical interview and M.I.N.I. The duration of the current depressive episode must be at least 4 weeks and no longer than 3 years in length.
  3. Should have a MADRS score of at least 20 at screening, an YMRS score of less than 12 and a CGI score of at least 4.
  4. Must have signed the document and have a level of understanding sufficient to provide informed consent and to communicate with the investigator and site personnel.
  5. Must be on a mood stabilizer acceptable to the study physician which is consistent with their diagnosis. The mood stabilizer must be at a stable dose for at least four days before starting TMS treatment.
  6. If female of , patients must

    1. have a negative urine pregnancy test at screening, and
    2. not be nursing or planning a pregnancy, and
    3. be on a medically acceptable method of acceptable to the principal investigator.

Choices of contraception that meet the study requirements are

  • Intrauterine device
  • Hormonal contraception (estrogen-containing birth control pills, Vaginal ring, patch, injections or implants)
  • Latex condom with spermicide
  • Diaphragm with spermicide
  • Cervical cap with spermicide

Females of childbearing potential who are abstinent can enroll in the study.

Exclusion criteria

Exclusion Criteria- Phase II:

  1. May not be directly affiliated with Sheppard Pratt Clinical Research Programs or be immediate family of Research Programs personnel.
  2. Must not have another primary Axis I diagnosis.
  3. The subject must not have stopped an antidepressant less than two weeks before starting TMS treatment or unable to discontinue antidepressant therapy.
  4. Should have no previous history of psychosis or substance dependence or abuse within the six months prior to Screening
  5. Presence of an Axis II disorder felt by the investigator to potentially interfere with study compliance would exclude a potential participant.
  6. Should not have prior intolerance of TMS or significant lack of response to adequate trials of TMS.
  7. Should not have a lifetime history of lack of response to ECT or VNS.
  8. Should not have any medical condition likely to interfere with safe study participation.
  9. Women of who are not using a medically accepted means of when engaging in sexual intercourse are excluded, as well as women who are pregnant or breast-feeding.
  10. Positive urine screen for any substance of abuse will exclude a patient, with the exception of benzodiazepines. A satisfactory explanation in the opinion of the investigator along with a negative repeat screen prior to Visit 2 is possibly acceptable.
  11. Current suicide risk, as evidenced:

    1. It is the judgment of the investigator that the patient may be at risk for suicide
    2. The patient has rated a "yes" to question 4 or question 5 on the Screening C-SSRS
    3. The patient has attempted suicide within the past 12 months prior to Screening.
  12. History of head injury, epilepsy or seizure disorder, non-removable metallic implants or objects in or around the head.

Inclusion Criteria- Phase III Patients who meet MADRS criteria for response or remission will enter Phase III, the six month follow-up phase of the study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Open-Label TMS

    Active Transcranial Magnetic Stimulation

    Device: NeuroStar TMS

Interventions

  • DeviceNeuroStar TMS

    Transcranial Magnetic Stimulation

    Also known as: Transcranial Magnetic Stimulation

06

What researchers measure

Primary outcomes

  1. The Percentage of Patients Who Respond or Remit After 30 to 35 Treatments Based Off of the Montgomery-Åsberg Depression Rating Scale (MADRS)

    The MADRS is a clinician rated scale measuring depression severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of 60; higher scores denote greater severity. A decrease in MADRS score of at lease 50% will be considered a response to treatment. A MADRS score of less than 10 will be considered remission.

    Time frame: Up to 7 weeks

  2. The Percentage of Patients Who Meet Criteria for Onset of Manic Symptoms Based on the Young Mania Rating Scale (YMRS).

    The Young Mania Rating Scale (YMRS) is used to determine the severity of a patient's mania. The score for the YMRS ranges form 0 to 60. Scores of 13-19 indicate minimal manic symptoms, 20-25 is mild mania, 26-37 is moderate mania, and 38-60 is severe mania. A YMRS score of 14 or greater will be used for criteria of onset of manic symptoms. The patients will be separated based on their diagnostic category of either Bipolar I Disorder or Bipolar II Disorder.

    Time frame: Up to 7 weeks

Secondary outcomes

  1. Hamilton Depression Rating Scale (HAM-D) to Calculate Percentage of Patients Meeting Response Criteria

    The Hamilton Depression (HAM-D) Rating Scale is a scale used to measure one's depression. The scoring from the scale ranges 0 to 53. Higher scores indicate that a person is more depressed. The scoring ranges from 0-7 is normal, 8-13 is mild depression, 14-18 is moderate depression, 19-22 severe depression, and greater than or equal to 23 is very severe depression. The HAM-D response criteria will be based off a HAM-D score drop of at least 50%. Remission HAM-D score will be 7 or less.

    Time frame: Up to 7 weeks

  2. Clinical Global Impression (CGI) to Calculate Percentage of Patients Meeting Response Criteria

    The Clinical Global Impression (CGI) Scale is used to determine the severity of a patient's depression. The scoring for the scale ranges from 1 to 7, where 1 indicates that the patient is normal and 7 indicates a severe depression. Remission criteria for the CGI score will be a 2 or less. Responders and remitters will also be followed for six months after the final treatment to see the durability of response. Percentage of patients' meeting relapse criteria will be calculated.

    Time frame: Up to 7 weeks and 6 Month Follow Up

  3. Hamilton Depression Rating Scale (HAM-D) to Average Number of Treatments Needed to Meet Remission

    For the patients meeting remission criteria (Total Number = 21) , we will calculate the number of treatments required to achieve remission. Patients who only meet response criteria will be treated for 30 to 35 sessions.

    Time frame: 7 Weeks

  4. Clinical Global Impression (CGI) to Calculate Average Number of Treatments Needed to Meet Remission

    For the patients meeting remission criteria (Total Number = 27) , we will calculate the number of treatments required to achieve remission. Patients who only meet response criteria will be treated for 30 to 35 sessions.

    Time frame: 7 Weeks

07

Results

Posted May 12, 2022
Limitations and caveats
Open label trial

Participant flow

Participant flow — Overall Study
MilestonePatients With Bipolar (I or II) Depression
Started31
Completed29
Not completed2
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryThe Percentage of Patients Who Respond or Remit After 30 to 35 Treatments Based Off of the Montgomery-Åsberg Depression Rating Scale (MADRS)

The MADRS is a clinician rated scale measuring depression severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of 60; higher scores denote greater severity. A decrease in MADRS score of at lease 50% will be considered a response to treatment. A MADRS score of less than 10 will be considered remission.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
The Percentage of Patients Who Respond or Remit After 30 to 35 Treatments Based Off of the Montgomery-Åsberg Depression Rating Scale (MADRS)
ParticipantsPatients With Bipolar (I or II) Depression
Response Criteria — Number meeting criteria27
Response Criteria — Number of non-responders4
Remission Criteria — Number meeting criteria23
Remission Criteria — Number of non-responders8
Statistical analysis
  • Patients With Bipolar (I or II) Depression · t-test, 2 sided · p = <0.001 (Paired t test for pre and post treatment scores for all subjects)
PrimaryThe Percentage of Patients Who Meet Criteria for Onset of Manic Symptoms Based on the Young Mania Rating Scale (YMRS).

The Young Mania Rating Scale (YMRS) is used to determine the severity of a patient's mania. The score for the YMRS ranges form 0 to 60. Scores of 13-19 indicate minimal manic symptoms, 20-25 is mild mania, 26-37 is moderate mania, and 38-60 is severe mania. A YMRS score of 14 or greater will be used for criteria of onset of manic symptoms. The patients will be separated based on their diagnostic category of either Bipolar I Disorder or Bipolar II Disorder.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
The Percentage of Patients Who Meet Criteria for Onset of Manic Symptoms Based on the Young Mania Rating Scale (YMRS).
ParticipantsPatients With Bipolar (I or II) Depression
Bipolar I Disorder20
Bipolar II Disorder11
Bipolar I Participants with Onset of Maniac Symptoms0
Bipolar II Participants with Onset of Maniac Symptoms0
Statistical analysis
  • Patients With Bipolar (I or II) Depression ·
SecondaryHamilton Depression Rating Scale (HAM-D) to Calculate Percentage of Patients Meeting Response Criteria

The Hamilton Depression (HAM-D) Rating Scale is a scale used to measure one's depression. The scoring from the scale ranges 0 to 53. Higher scores indicate that a person is more depressed. The scoring ranges from 0-7 is normal, 8-13 is mild depression, 14-18 is moderate depression, 19-22 severe depression, and greater than or equal to 23 is very severe depression. The HAM-D response criteria will be based off a HAM-D score drop of at least 50%. Remission HAM-D score will be 7 or less.

Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Hamilton Depression Rating Scale (HAM-D) to Calculate Percentage of Patients Meeting Response Criteria
ParticipantsPatients With Bipolar (I or II) Depression
Remission : Met criteria21
Remission : Non-responders10
Response : Met criteria24
Response : Non-responders7
SecondaryClinical Global Impression (CGI) to Calculate Percentage of Patients Meeting Response Criteria

The Clinical Global Impression (CGI) Scale is used to determine the severity of a patient's depression. The scoring for the scale ranges from 1 to 7, where 1 indicates that the patient is normal and 7 indicates a severe depression. Remission criteria for the CGI score will be a 2 or less. Responders and remitters will also be followed for six months after the final treatment to see the durability of response. Percentage of patients' meeting relapse criteria will be calculated.

Time frame:
Up to 7 weeks and 6 Month Follow Up
Reported as:
Count of participants · Participants
Clinical Global Impression (CGI) to Calculate Percentage of Patients Meeting Response Criteria
ParticipantsPatients With Bipolar (I or II) Depression
Remission Criteria During 7 Week Treatment — Met criteria27
Remission Criteria During 7 Week Treatment — Did not meet criteria4
Relapse Criteria During 6 Month Follow Up — Met criteria9
Relapse Criteria During 6 Month Follow Up — Did not meet criteria22
SecondaryHamilton Depression Rating Scale (HAM-D) to Average Number of Treatments Needed to Meet Remission

For the patients meeting remission criteria (Total Number = 21) , we will calculate the number of treatments required to achieve remission. Patients who only meet response criteria will be treated for 30 to 35 sessions.

Time frame:
7 Weeks
Reported as:
Mean · Number of Treatments
Hamilton Depression Rating Scale (HAM-D) to Average Number of Treatments Needed to Meet Remission
Number of TreatmentsPatients With Bipolar (I or II) Depression
Hamilton Depression Rating Scale (HAM-D) to Average Number of Treatments Needed to Meet Remission25.76 ± 5.02
SecondaryClinical Global Impression (CGI) to Calculate Average Number of Treatments Needed to Meet Remission

For the patients meeting remission criteria (Total Number = 27) , we will calculate the number of treatments required to achieve remission. Patients who only meet response criteria will be treated for 30 to 35 sessions.

Time frame:
7 Weeks
Reported as:
Mean · Number of Treatments
Clinical Global Impression (CGI) to Calculate Average Number of Treatments Needed to Meet Remission
Number of TreatmentsPatients With Bipolar (I or II) Depression
Clinical Global Impression (CGI) to Calculate Average Number of Treatments Needed to Meet Remission26.48 ± 4.45

Adverse events

Collected over Six months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients With Bipolar (I or II) Depression0/31 (0%)0/31 (0%)1/31 (3.2%)
Most frequent other events
Most frequent other events
EventPatients With Bipolar (I or II) Depression
AgitationPsychiatric disorders1/31

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Patients With Bipolar (I or II) Depression
<=18 years0
Between 18 and 65 years30
>=65 years1
Age, Continuous
Age, Continuous(years)Patients With Bipolar (I or II) Depression
Mean42.2 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)Patients With Bipolar (I or II) Depression
Female18
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Patients With Bipolar (I or II) Depression
Hispanic or Latino0
Not Hispanic or Latino31
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients With Bipolar (I or II) Depression
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White29
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Patients With Bipolar (I or II) Depression
United States31
Montgomery-Åsberg Depression Rating Scale
Montgomery-Åsberg Depression Rating Scale(Number of participants)Patients With Bipolar (I or II) Depression
Participants in remission at baseline0
Participants responding at baseline0
08

Study locations

2 sites
  • Sheppard Pratt Health System
    Baltimore, Maryland 21204, United States
  • Department of Psychiatry and Psychology, Mayo Clinic
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Jul 2020 and a completion of Jul 2020. It does not say whether these dates are actual or estimated.

Results were first posted in May 2022, 1 year 10 months after primary completion. A results delay was requested in Sep 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2015
First posted
Dec 29, 2015
Start
Dec 2015
Primary completionActual
Jul 2020
CompletionActual
Jul 2020
Results delay requested
Sep 20, 2021
Results first posted
May 12, 2022
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02640950
Lead sponsor
Sheppard Pratt Health System
Collaborators
Mayo Clinic
Responsible party
Scott T. Aaronson, M.D (Director, Clinical Research Programs, Sheppard Pratt Health System) — Principal investigator
First posted
Dec 29, 2015
Start date
Dec 2015
Primary completion
Jul 2020
Completion
Jul 2020
Results posted
May 12, 2022
Last update
Jun 1, 2022

Study contacts

Scott T Aaronson, MD
principal investigator · Sheppard Pratt Health System

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion